Neuroprotective effects of iron chelator Desferal on dopaminergic neurons in the substantia nigra of rats with iron-overload

被引:80
作者
Jiang, Hong [1 ]
Luan, Zhuo [1 ]
Wang, Jun [1 ]
Xie, Junxia [1 ]
机构
[1] Qingdao Univ, Coll Med, Dept Physiol, Qingdao 266021, Peoples R China
基金
中国国家自然科学基金;
关键词
Desferal; iron; Parkinson's disease; dopaminergic neurone; substantia nigra;
D O I
10.1016/j.neuint.2006.04.015
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The aim of the present study was to investigate whether the iron chelator Desferal prevents the degeneration of dopaminergic neurons in the substantia nigra (SN) induced by iron-overload in rats. Using fast cyclic voltammetry, tyrosine hydroxylase (TH) immunohistochemistry, Perls' iron staining, and high-performance liquid chromatography-electrochemical detection, we measured the degeneration of dopaminergic neurons and increased iron content in the SN of rats overloaded with iron dextran and assessed the effects of treatment with Desferal. The results showed that iron dextran overload increased the iron content in the SN, decreased dopamine release and content, and reduced the numbers of TH-immunoreactive neurons. Treatment with Desferal prevented the increased iron content in the SN. As a result, dopamine release and content remained at almost normal levels, while the numbers of TH-immunoreactive neurons remained at control values. This study suggests that the iron chelator Desferal is neuroprotective against iron-overload, so iron chelators that can cross the blood-brain barrier may have the potential to treat cases where abnormal iron accumulation in the brain is associated with the degenerative processes, as in Parkinson's disease. (c) 2006 Elsevier Ltd. All rights reserved.
引用
收藏
页码:605 / 609
页数:5
相关论文
共 32 条
[1]   Determinants of platelet responsiveness to nitric oxide in patients with chronic heart failure [J].
Anderson, RA ;
Ellis, GR ;
Chirkov, YY ;
Holmes, AS ;
Payne, N ;
Blackman, DJ ;
Jackson, SK ;
Lewis, MJ ;
Horowitz, JD ;
Frenneaux, MP .
EUROPEAN JOURNAL OF HEART FAILURE, 2004, 6 (01) :47-54
[2]   Neuroprotection by a novel brain permeable iron chelator, VK-28, against 6-hydroxydopamine lession in rats [J].
Ben Shachar, D ;
Kahana, N ;
Kampel, V ;
Warshawsky, A ;
Youdim, MBH .
NEUROPHARMACOLOGY, 2004, 46 (02) :254-263
[3]   THE IRON CHELATOR DESFERRIOXAMINE (DESFERAL) RETARDS 6-HYDROXYDOPAMINE-INDUCED DEGENERATION OF NIGROSTRIATAL DOPAMINE NEURONS [J].
BENSHACHAR, D ;
ESHEL, G ;
FINBERG, JPM ;
YOUDIM, MBH .
JOURNAL OF NEUROCHEMISTRY, 1991, 56 (04) :1441-1444
[4]   Iron accumulation in the substantia nigra in rats visualized by ultrasound [J].
Berg, D ;
Grote, C ;
Rausch, WD ;
Mäurer, M .
ULTRASOUND IN MEDICINE AND BIOLOGY, 1999, 25 (06) :901-904
[5]   Neonatal iron exposure induces oxidative stress in adult Wistar rat [J].
Dal-Pizzol, F ;
Klamt, F ;
Frota, MLC ;
Andrades, ME ;
Caregnato, FF ;
Vianna, MMR ;
Schröder, N ;
Quevedo, J ;
Izquierdo, I ;
Archer, T ;
Moreira, JCF .
DEVELOPMENTAL BRAIN RESEARCH, 2001, 130 (01) :109-114
[6]   Novel multifunctional neuroprotective iron chelator-monoamine oxidase inhibitor drugs for neurodegenerative diseases. In vivo selective brain monoamine oxidase inhibition and prevention of MPTP-induced striatal dopamine depletion [J].
Gal, S ;
Zheng, H ;
Fridkin, M ;
Youdim, MBH .
JOURNAL OF NEUROCHEMISTRY, 2005, 95 (01) :79-88
[7]   Ascorbyl radical/ascorbate ratio in plasma from iron overloaded rats as oxidative stress indicator [J].
Galleano, M ;
Aimo, L ;
Puntarulo, S .
TOXICOLOGY LETTERS, 2002, 133 (2-3) :193-201
[8]   The potential role of iron chelators in the treatment of Parkinson's disease and related neurological disorders [J].
Gassen, M ;
Youdim, MBH .
PHARMACOLOGY & TOXICOLOGY, 1997, 80 (04) :159-166
[9]  
Glinka Y, 1996, J NEUROCHEM, V66, P2004
[10]   Oxidative stress in Parkinson's disease [J].
Jenner, P .
ANNALS OF NEUROLOGY, 2003, 53 :S26-S36